EAST WINDSOR, N.J. – Aurobindo Pharma USA announces the launch of Citalopram Capsules. Citalopram Capsules are indicated for the treatment of Major Depressive Disorder (MDD) in adults.
According to IQVIA, U.S. annual sales for Citalopram Capsules were approximately $5.1 million for the 12 months ending Jan 2026.
Product Details:
• Strength: 30 mg Prescribing Information
For more details on Aurobindo’s Citalopram Capsules, visit Citalopram Capsules 30 mg -30/Bottle | Aurobindo Pharma USA
With a presence in over 150 countries, Aurobindo Pharma is a global leader in developing, manufacturing, and marketing generic pharmaceuticals, APIs, and injectables. Headquartered in Hyderabad, Aurobindo is driven by a mission to deliver superior customer service, leveraging vertical integration and efficient controlled processes.
